Completed PHASE1 INTERVENTIONAL 2-arm NCT01802918

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects

Sponsor: GlaxoSmithKline

Conditions Infection, Human Immunodeficiency Virus

Interventions GSK2838232 Placebo Ritonavir

Updated 7 times since 2017 Last updated: May 5, 2017 Started: Feb 18, 2013 Primary completion: Nov 21, 2013 Completion: Nov 21, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01802918, this PHASE1 trial focuses on Infection, Human Immunodeficiency Virus and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jul 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jul 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States